

Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

ARTICLE

Three-component synthesis of fluorinated pyrazoles from fluoroalkylamines, NaNO₂ and electron-deficient alkynes

Cite this: DOI: 10.1039/x0xx00000x

Pavel K. Mykhailiuk^{a,b*}Received 00th January 2014,
Accepted 00th January 2014

DOI: 10.1039/x0xx00000x

www.rsc.org/

Three-component reaction between RCF₂CH₂NH₂*HCl, NaNO₂ and alkynes drastically depends on substituents "R" and "R¹". The reaction gives the fluorinated pyrazoles in high yields when "R" is fluorine atom or fluoroalkyl group, and "R¹" is an electron-withdrawing substituent. With other "R" unexpected products are formed.

Introduction

Fluorinated heterocycles play a role in medicinal chemistry and agrochemistry.^{1,2} In particular, pyrazoles with diverse fluoroalkyl groups often comprise to bioactive molecules (Figure 1).^{3,4} Therefore, elaboration of practical and general methods to novel fluoroalkyl-substituted pyrazoles is truly important.





Fig. 1. Drugs and agrochemicals – derivatives of pyrazoles with diverse fluoroalkyl groups.


Among other methods to introduce fluoroalkyl groups into organic compounds,⁵ CF₃CHN₂ is worth mentioning. In 1943 Gilman and Jones synthesized this reagent from trifluoroethyl amine hydrochloride and sodium nitrite.⁶ Since then CF₃CHN₂ blossoms in organic chemistry⁷ and many research groups have been using it.⁸ In particular, recently a three-component reaction between CF₃CH₂NH₂*HCl (1), NaNO₂ and alkynes

(Scheme 1, a) towards CF₃-substituted pyrazoles was elaborated.⁹ Mechanistically, the reaction proceeded via *in situ*-generated of CF₃CHN₂, followed by [3+2]-cycloaddition with alkynes. Later, this transformation was expanded towards C₂F₅-pyrazoles starting from amine 2 (Scheme 1, a).¹⁰ In both cases, however, only the electron-deficient alkynes reacted. Given that the target CF₃-/C₂F₅-pyrazoles were synthesized in high yield and gram scale, herein I wanted to answer the following questions: is this reaction universal? Can other fluoroalkyl amines (scope of "R") be used? Can other alkynes (scope of "R¹") be used (Scheme 1, b)?

Previous work (a)



This work (b)



Scheme 1. (a) Literature data.^{9,10a} (b) Aim of this work.













Results and Discussion

Scope of amines

To study the scope of the reaction, a model alkyne was selected first – methyl propiolate. Then, diverse amine hydrochlorides RCF₂CH₂NH₂*HCl (3–10*HCl) were tested under the previously discovered conditions.⁹ In particular, a mixture of an amine, NaNO₂ and methyl propiolate was stirred

in dichloromethane/water at room temperature for three days. The obtained unexpected results are summarized in Table 1.


Table 1. Scope of the reaction: amines.

Amine	R	Product	Yield ^a	Path
1	F		99% (X-Ray) ⁹	"a"
2	CF ₃		99% ^{10a}	"a"
3	H ₂ NCH ₂ C ₃ F ₆		87% ^b	"a"
4	CHF ₂		97%	"a"
5	CO ₂ Me		51% ^c (X-Ray)	"b"
6	Ph	 + 	17% ^d 10% ^d (X-Ray)	"b" "c"
7	H		[ca. 50%] ^e	"b"
8	HOCH ₂		31% ^c (X-Ray)	"c"
9	Et	 + 	7% 21%	"c" "d"
10	BocNHCH ₂		47% ^c (X-Ray)	"e"

^aIsolated yields. ^b0.5 eq. of amine (H₂NCH₂C₃F₆)₂*2HCl were used. ^c1.0 eq. of amine RCF₂CH₂NH₂*HCl was used. ^dProduct **6b** was of 80% purity. ^eYield according to NMR of the reaction mixture.

Amine hydrochlorides **3***HCl and **4***HCl with fluorinated electron-withdrawing substituents gave the expected pyrazoles **3a** and **4a** in good yields of 87% and 97%, respectively.

Obviously, the reaction proceeded via *in situ* formation of RCF₂CHN₂ (Scheme 2, Path "a").



Scheme 2. Proposed mechanistic profile of the reaction.

The reaction of amine hydrochloride **5***HCl with non-fluorinated electron-withdrawing substituent (CO₂Me), unexpectedly gave the pure diazo ketone **5b** (X-Ray, Figure 2) in 51% yield and the starting alkyne. Presumably, the initially formed fluorinated diazo intermediate "Y" underwent acid-catalyzed aqueous hydrolysis (Scheme 2, Path "b"). Individual diazo ketone **5b**, in turn, did not react with methyl propiolate even under heating.

Amine hydrochloride **6***HCl gave even more astonishing results: along with many unidentified products, diazo ketone **6b**, and pure isoxazole **6c** (X-Ray, Figure 2) were isolated in poor yields. Although the mechanism of formation of isoxazole **6c** is not totally clear, it seems that the initially formed ketone **6b** reacted with HNO₂ to give intermediate "Z" that further transformed into nitroxide "W". [3+2]-cycloaddition of "W" with methyl propiolate might have given isoxazole **6c** (Scheme 2, Paths "b" and "c").¹¹ Indeed, additional mechanistic studies are needed to support/reject this suggestion (that is outside the scope of this work).

Reaction of amine hydrochloride **7***HCl gave no pyrazole-containing products, but unidentified side materials, the starting alkyne and diazo acetaldehyde **7b**. The pure compound **7b** was described in the literature before – in CDCl₃ it exists as a mixture of *cis*- and *trans*-rotamers that have very characteristic signals in ¹H NMR.¹² Worth mentioning, that previously *Atherton*, *Fields*, and *Haszeldine* also tried to generate CF₂HCHN₂, but with no success.¹³

Amine hydrochloride **8***HCl also afforded isoxazole **8d** (X-Ray, Figure 2) as a main reaction product (Scheme 2, Path "c").

Amine hydrochloride **9***HCl with an alkyl substituent (Et) provided the complex mixture from which the two pure products were obtained: minor isoxazole **9c** and major pyrazole **9d** (Scheme 2, Paths "c" and "d"). Presumably, the initially

formed alkyl diazo ketone EtCOCHN₂ was quite active to rapidly react with methyl propylate (**9d**), rather than to be transformed into nitroxide (and subsequently into **9c**).

Amine hydrochloride **10***HCl gave pure cyclic product **10e** (*X-Ray*, Figure 2) in 59% yield (Scheme 2, Path “e”). In this reaction no pyrazole/isoxazole-containing products was observed in any significant amounts.

In a short summary, the studied reaction (Scheme 1) gives the needed fluorinated pyrazoles only if substituent “R” is F-atom (**1**) or fluoroalkyl group (**2-4**). Although only three groups - CF₃, C₂F₄H and C₃F₆X - were tested, it seems that the reaction would also work for all fluoroalkyl substituents “R”. With other substituents “R” - H, Alk, Ar, CO₂Alk (**5-10**), - the reaction gives unexpected products in low to moderate yields. Although, detailed mechanistic studies are needed to explain formation of these compounds (which is outside of the scope of the current project), the putative overall mechanistic profile is summarized in Scheme 2. These suggestions are supported by *X-Ray* data of all products and stable intermediates (Figure 2).




Fig. 2. X-Ray crystallographic structures of compounds **5b**, **6c**, **7c**, and **10e**.¹⁴

Scope of alkynes

Previously, we showed that *in situ*-generated FCF₂CHN₂ and CF₃CF₂CHN₂ reacted at room temperature only with electron-deficient alkynes.^{9,10a} The reactivity of HCF₂CF₂CHN₂, however, could differ much, because HCF₂-substituent is a significantly weaker acceptor than the F- and CF₃-ones.¹⁵ Therefore, amine hydrochloride **4***HCl was selected next, and its reactivity was tested towards diverse alkynes (Table 2).¹⁶

It was experimentally found that amine **4** behaved similar to the previously reported amines **1** and **2** (Table 2). In fact, electron-deficient alkynes **12-19** smoothly reacted to give pyrazoles **12a-19a** in excellent yields of 91-97%. The reaction was extremely clean - no side products, - and practical - evaporation of organic phase afforded the pure pyrazoles without any further purification. For mono-substituted alkynes, regioselective formation of only 3,5-disubstituted pyrazoles was observed, that was supported by *X-Ray* studies (Figure 3).

While heterocyclic alkyne **20** gave pyrazole **20a** in good yield of 73%, aromatic less- (**21**) or none activated (**22**) alkynes did not react, however.

Table 2. Scope of the reaction: alkynes.

Alkyne	Product	Yield (%) ^a
	4a	97
	12a	97
	13a	96 (<i>X-Ray</i>)
	14a	96
	15a	95
	16a	94
	17a	91
	18a	92
	19a	93 (<i>X-Ray</i>)
	20a	73 ^b
	<i>no reaction</i> ^b	
	<i>no reaction</i> ^b	

^a Isolated yields. ^b 5.0 eq. of amine **4** were used

In short summary, the studied reaction (Scheme 1) gives the needed fluorinated pyrazoles only with electron-deficient alkynes. The nature of fluoroalkyl-substituent “R” (F, CF₃,

CHF₂, etc) in amines does not have any significant impact on the reactivity of the corresponding diazo intermediate RCF₂CHN₂, and hence on the selection of alkynes.





Fig. 3. X-Ray crystallographic structures of compounds **13a**, **19a**.¹⁷

Conclusions

The studied reaction towards fluorinated pyrazoles (Schemes 1, 3) is universal. It ideally works if substituent “R” is F-atom or fluoroalkyl group, and substituent R¹ is an electron-withdrawing group (EWG). With other “R” the reaction gives unexpected products in low yields. This method is highly practical: it works under air, in common solvents (water, dichloromethane), without any catalysts and at room temperature. Moreover, it gives pyrazoles in excellent yields, and mostly without purification (just evaporation of an organic phase). Gram quantities of the products can be rapidly synthesized. I believe that the developed useful protocol will find very soon wide practical application in medicinal chemistry and agrochemistry – areas, where fluoroalkyl pyrazoles play an important role.



Scheme 3. Scope of three-component synthesis of fluorinated pyrazoles.

Experimental part

Dichloromethane was purified by distillation. All reagents were available from Enamine Ltd. Melting points are uncorrected. ¹H- and ¹³C-NMR spectra were recorded on a Bruker Avance 500 spectrometer (at 499.9 MHz and 124.9 MHz, respectively). ¹⁹F-NMR spectra were recorded on a Varian Unity Plus 400 spectrometer (at 376.7 Hz). Chemical shifts are reported in ppm downfield from Me₄Si (¹H, ¹³C) or upfield from CFCl₃ (¹⁹F) using conventional deuterium lock referencing as internal standards. MS analysis was performed on an LCMS instrument with chemical ionization, or on GCMS with ionization by electrospray.

General procedure

Representative synthesis:

Methyl 3-(pentafluoroethyl)-1H-pyrazole-5-carboxylate (**2a**)

To a stirred suspension of C₂F₅CH₂NH₂·HCl (120 mg, 0.64 mmol, 2.0 eq.) in CH₂Cl₂ (8.0 mL) / water (0.4 mL), sodium nitrite (64 mg, 0.96 mmol, 3.0 eq.) and methyl propylate (26 mg, 0.32 mmol, 1.0 eq.) were added. The reaction mixture was vigorously stirred 72 h at 20 °C. Water (2.0 mL) and CH₂Cl₂ (6 mL) were added. The organic layer was separated. The aqueous layer was washed with CH₂Cl₂ (2 × 6 mL). The combined organic layers were dried over Na₂SO₄ and evaporated under vacuum to provide the pure product **2a** as a white solid (78 mg, 99%). M.p. = 79-80 °C.

¹H NMR (500 MHz; CDCl₃; Me₄Si), δ: 11.81 (broad s, 1H, NH), 7.11 (s, 1H, CH), 3.96 (s, 3H, CH₃).

¹³C NMR (125 MHz; CDCl₃; Me₄Si), δ: 159.0 (s, CO), 142.8 (broad s, C), 135.5 (broad s, C), 118.6 (qt, ¹J_{C-F} = 285 Hz, ²J_{C-F} = 36 Hz, CF₂CF₃), 110.2 (tq, ¹J_{C-F} = 250 Hz, ²J_{C-F} = 39 Hz, CF₂CF₃), 108.6 (s, CH), 52.7 (s, CH₃).

¹⁹F NMR (375 MHz; CDCl₃; CFCl₃), δ: -85.1 (s, 3F, CF₂CF₃), -113.8 (s, 2F, CF₂CF₃).

MS (CI): *m/z* (%) = 245 [M+1]⁺.

Anal. calcd for C₇H₅F₅N₂O₂: C, 34.44; H, 2.06; N, 11.48. Found: C, 34.14; H, 2.34; N, 11.68.

Dimethyl 3,3'-(1,1,2,2,3,3,4,4-octafluorobutane-1,4-diyl)bis(1H-pyrazole-5-carboxylate) (**3a**)

The reaction was performed following the general procedure, except for: 0.5 eq. (H₂NCH₂CF₂CF₂)₂·2HCl + 1.0 eq. methyl propylate + 2 eq. NaNO₂. After 72 h at 20 °C, the reaction mixture was placed into the fridge at 0 °C for 12h. The formed light-yellow precipitate was filtered off, washed with water, and dried on air. Yellow solid (125 mg, 87%). M.p. > 200 °C.

¹H NMR (500 MHz; DMSO-d₆; Me₄Si), δ: 7.20 (s, 2H, CH), 3.86 (s, 6H, CH₃).

¹³C NMR (125 MHz; DMSO-d₆; Me₄Si), δ: 158.9 (s, CO), 140.8 (broad s, C), 135.6 (broad s, C), one CF₂ is not seen, 109.4 (tt, ¹J_{C-F} = 250 Hz, ²J_{C-F} = 38 Hz, CF₂), 108.6 (s, CH), 52.5 (s, CH₃).

¹⁹F NMR (375 MHz; DMSO-d₆; CFCl₃), δ: -108.1 (t, *J* = 11.3 Hz, 4F, CF₂), -121.5 (t, *J* = 11.3 Hz, 4F, CF₂).

MS (CI): *m/z* (%) = 451 [M+1]⁺.

Anal. calcd for C₁₄H₁₀F₈N₄O₄: C, 37.35; H, 2.24; N, 12.44. Found: C, 37.11; H, 2.03; N, 12.78.

Methyl 3-(1,1,2,2-tetrafluoroethyl)-1H-pyrazole-5-carboxylate (**4a**)

The reaction was performed following the general procedure. White solid (70 mg, 97%). M.p. 67-68 °C.

¹H NMR (500 MHz; CDCl₃; Me₄Si), δ: 7.12 (s, 1H, CH), 6.13 (t, *J* = 52.0 Hz, 1H, CHF₂), 3.97 (s, 3H, CH₃).

¹³C NMR (125 MHz; CDCl₃; Me₄Si), δ: 159.1 (s, CO), 143.2 (t, *J* = 30 Hz, C), 135.1 (s, C), 109.3 (tt, ¹J_{C-F} = 250 Hz, ²J_{C-F} = 38 Hz, CF₂), *tetr*-CF₂ is not seen, 108.1 (s, CH), 52.4 (s, CH₃).

¹⁹F NMR (375 MHz; CDCl₃; CFCl₃), δ: -113.6 (broad s, 2F, CF₂), -136.4 (dt, ²J_{F-H} = 52.0 Hz, ²J_{F-F} = 7.5 Hz).

MS (CI): *m/z* (%) = 227 [M+1]⁺.

Anal. calcd for C₇H₆F₄N₂O₂: C, 37.18; H, 2.67; N, 12.39. Found: C, 37.45; H, 2.32; N, 12.71.

Methyl 3-diazo-2-oxopropanoate (**5b**)

The reaction was performed following the general procedure, except for: 1 eq. $\text{MeO}_2\text{CCF}_2\text{CH}_2\text{NH}_2\cdot\text{HCl}$ + 1.0 eq. methyl propylate + 3.0 eq. NaNO_2 . ^1H NMR of the crude reaction mixture revealed the starting alkyne, diazo compound **5b** and an unidentified side product (5-10% mol). The isolated reaction mixture was left at 20 °C for 24 h, whereas the partial crystallization occurred. The mixture was washed with cyclohexane (0.5 mL) to remove the liquid products (the alkyne and the side product). The remaining white solid was dried on air to afford the diazo ketone **5b** (42 mg, 51%). M.p. 44-45 °C (*dec.*)

^1H NMR (500 MHz; CDCl_3 ; Me_4Si), δ : 6.18 (s, 1H, CH), 3.88 (s, 3H, CH_3).

^{13}C NMR (125 MHz; CDCl_3 ; Me_4Si), δ : 176.1 (s, CO), 160.4 (s, CO), 56.7 (s, CH), 53.0 (s, CH_3).

MS (ES): m/z (%) = 128 $[\text{M}]^+$.

Anal. calcd for $\text{C}_4\text{H}_4\text{N}_2\text{O}_3$: C, 37.51; H, 3.15; N, 21.87. Found: C, 37.15; H, 3.38; N, 21.69.

The experiment was also performed on 4-times larger scale, all results being reproducible.

2-Diazo-1-phenylethanone (6b),

Methyl 3-benzoylisoxazole-5-carboxylate (6c)

The reaction was performed following the general procedure, except for: 1 eq. $\text{PhCF}_2\text{CH}_2\text{NH}_2\cdot\text{HCl}$ + 1.0 eq. methyl propylate + 3.0 eq. NaNO_2 . The crude reaction mixture was purified by column chromatography using hexane/EtOAc = 5/1 as an eluent. The fraction with R_F = 0.4 (11 mg) contained ca. 90% of isoxazole **6c**. This fraction was recrystallized from cyclohexane to afford the pure isoxazole **6c** (8 mg, 10%) as a white solid. M.p. 95-96 °C.

^1H NMR (500 MHz; CDCl_3 ; Me_4Si), δ : 8.32 (d, J = 8.0 Hz, 2H, Ph), 7.69 (t, J = 8.0 Hz, 1H, Ph), 7.55 (t, J = 8.0 Hz, 2H, Ph), 7.41 (s, 1H, CH), 4.02 (s, 3H, CH_3).

^{13}C NMR (125 MHz; CDCl_3 ; Me_4Si), δ : 184.0 (s, CO), 161.8 (s), 160.4 (s), 156.3 (s), 134.8 (s), 134.1 (s), 130.3 (s), 128.4 (s), 109.9 (s), 52.8 (s, CH_3).

MS (ES): m/z (%) = 231 $[\text{M}]^+$.

Anal. calcd for $\text{C}_{12}\text{H}_9\text{NO}_4$: C, 62.34; H, 3.92; N, 6.06. Found: C, 62.71; H, 3.59; N, 6.44.

Fraction with R_F = 0.3 (8 mg, 17%) contained ca. 90% of diazoketone **6b**.

^1H NMR (500 MHz; CDCl_3 ; Me_4Si), δ : 7.75 (d, J = 8.0 Hz, 2H, Ph), 7.55 (t, J = 8.0 Hz, 1H, Ph), 7.45 (t, J = 8.0 Hz, 2H, Ph), 7.91 (s, 1H, CH).

^1H NMR of **6b** was identical to that described for the individual compound.

The experiment was also performed on 10-times larger scale, all results being reproducible.

Methyl 3-glycolylisoxazole-5-carboxylate (8c)

The reaction was performed following the general procedure, except for: 1 eq. $\text{HOCH}_2\text{CF}_2\text{CH}_2\text{NH}_2\cdot\text{HCl}$ + 1.0 eq. methyl propylate + 3.0 eq. NaNO_2 . ^1H NMR of the crude reaction mixture revealed ca. 50% of isoxazole **8c**. The oil+crystalline reaction mixture was washed with cyclohexane (0.5 mL) to give the pure isoxazole **8c** (18 mg, 31%) as a white solid. M.p. 158-159 °C.

^1H NMR (500 MHz; DMSO-d_6 ; Me_4Si), δ : 7.58 (s, 1H, CH), 5.50 (broad s, 1H, OH), 4.77 (broad s, 2H, CH_2), 3.92 (s, 3H, CH_3).

^{13}C NMR (125 MHz; DMSO-d_6 ; Me_4Si), δ : 192.6 (s, CO), 161.0 (s), 160.3 (s), 156.3 (s), 108.1 (s), 66.1 (s, CH_2), 53.3 (s, CH_3).

MS (ES): m/z (%) = 185 $[\text{M}]^+$.

Anal. calcd for $\text{C}_7\text{H}_7\text{NO}_5$: C, 45.41; H, 3.81; N, 7.57. Found: C, 45.05; H, 4.12; N, 7.33.

The experiment was also successfully performed on 4-times larger scale.

Methyl 3-propionylisoxazole-5-carboxylate (9c),

Methyl 3-propionyl-1H-pyrazole-5-carboxylate (9d)

The reaction was performed following the general procedure. The crude reaction mixture was purified by column chromatography using hexane/EtOAc = 1/1 as an eluent. The fraction with R_F = 0.7 contained the pure isoxazole **9c** (4 mg, 7%) as a white crystalline. M.p. 53-54 °C.

^1H NMR (500 MHz; CDCl_3 ; Me_4Si), δ : 7.26 (s, 1H, CH), 4.00 (s, 3H, OCH_3), 3.12 (q, J = 8.0 Hz, 2H, CH_2CH_3), 1.24 (q, J = 8.0 Hz, 3H, CH_2CH_3).

^{13}C NMR (125 MHz; CDCl_3 ; Me_4Si), δ : 193.7 (s, CO), 161.5 (s), 161.0 (s), 144.3 (s), 107.4 (s), 52.8 (s, OCH_3), 33.1 (s, CH_2), 6.7 (s, CH_3).

MS (ES): m/z (%) = 183 $[\text{M}]^+$.

Anal. calcd for $\text{C}_8\text{H}_9\text{NO}_4$: C, 52.46; H, 4.95; N, 7.65. Found: C, 52.22; H, 5.27; N, 7.31.

The fraction with R_F = 0.3 contained the pure isoxazole **9d** (12 mg, 21%) as a white solid. M.p. 116-117 °C.

^1H NMR (500 MHz; CDCl_3 ; Me_4Si), δ : 7.33 (s, 1H, CH), 3.96 (s, 3H, CH_3), 2.99 (q, J = 7.0 Hz, 2H, CH_2), 1.23 (t, J = 7.0 Hz, 3H, CH_3).

^{13}C NMR (125 MHz; CDCl_3 ; Me_4Si), δ : 193.7 (s, CO), 160.6 (s, CO), 109.5 (s, CH), tert-C are not seen, 53.3 (s), 32.2 (s), 7.4 (s).

MS (CI): m/z (%) = 183 $[\text{M}+1]^+$.

Anal. calcd for $\text{C}_8\text{H}_{10}\text{N}_2\text{O}_3$: C, 52.74; H, 5.53; N, 15.38. Found: C, 52.41; H, 5.25; N, 15.69.

The experiment was also performed on 5-times larger scale.

5,5-Difluoro-1,3-oxazinan-2-one (10e)

The reaction was performed following the general procedure, except for: 1 eq. $\text{BocNHCH}_2\text{CF}_2\text{CH}_2\text{NH}_2\cdot\text{HCl}$ + 1.0 eq. methyl propylate + 3.0 eq. NaNO_2 . The oil+crystalline crude reaction mixture was washed with cyclohexane (0.5 mL) to give the pure product **10e** (21 mg, 47%) as a white crystalline. M.p. 66-67 °C.

^1H NMR (500 MHz; CDCl_3 ; Me_4Si), δ : 6.41 (broad s, 1H, NH), 4.37 (t, J = 10.5 Hz, 4H, CH_2), 3.69 (t, J = 10.5 Hz, 4H, CH_2).

^{13}C NMR (125 MHz; CDCl_3 ; Me_4Si), δ : 152.0 (s, CO), 113.6 (t, J = 244 Hz, CF_2), 67.2 (t, J = 33 Hz, CH_2CF_2), 46.4 (t, J = 33 Hz, CH_2CF_2).

^{19}F NMR (375 MHz; CDCl_3 ; CFCl_3), δ : -112.3 (qv, $^3J(\text{F},\text{H})$ = 11.3 Hz, 2F, CF_2).

MS (ES): m/z (%) = 137 $[\text{M}]^+$.

Anal. calcd for $\text{C}_4\text{H}_3\text{F}_2\text{NO}_2$: C, 35.05; H, 3.68; N, 10.22. Found: C, 35.43; H, 3.46; N, 10.57.

Ethyl 3-(1,1,2,2-tetrafluoroethyl)-1H-pyrazole-5-carboxylate (12a)

Compound **12a** was obtained as a white solid (74 mg, 97%) following the general procedure. M.p. = 67-68 °C.

¹H NMR (500 MHz; CDCl₃; Me₄Si), δ: 7.09 (s, 1H, CH), 6.11 (t, *J* = 52.0 Hz, 1H, CHF₂), 4.40 (q, *J* = 7.0 Hz, 2H, CH₂CH₃), 1.38 (t, *J* = 7.0 Hz, 3H, CH₂CH₃).

¹³C NMR (125 MHz; CDCl₃; Me₄Si), δ: 158.6 (s, CO), 143.5 (t, *J* = 30 Hz, C), 135.3 (s, C), 111.7 (tt, ¹*J*_{C-F} = 245 Hz, ²*J*_{C-F} = 28 Hz, CF₂), 109.3 (tt, ¹*J*_{C-F} = 250 Hz, ²*J*_{C-F} = 38 Hz, CF₂), 107.9 (s, CH), 61.8 (s, OCH₂), 13.8 (s, CH₃).

¹⁹F NMR (375 MHz; CDCl₃; CFCl₃), δ: -113.6 (pseudo q, *J* = 4.0 Hz, 2F, CF₂), -136.5 (dt, ²*J*_{F-H} = 52.0 Hz, ²*J*_{F-F} = 4.0 Hz).

MS (CI): *m/z* (%) = 241 [M+1]⁺.

Anal. calcd for C₈H₈F₄N₂O₂: C, 40.01; H, 3.36; N, 11.66. Found: C, 40.33; H, 3.72; N, 11.47.

Isopropyl 3-(1,1,2,2-tetrafluoroethyl)-1H-pyrazole-5-carboxylate (13a)

Compound **13a** was obtained as a white solid (78 mg, 96%) following the general procedure. M.p. = 72-73 °C.

¹H NMR (500 MHz; CDCl₃; Me₄Si), δ: 7.08 (s, 1H, CH), 6.11 (tt, ²*J*_{H-F} = 52.0 Hz, ³*J*_{H-F} = 16.0 Hz, 1H, CHF₂CF₂), 5.27 (m, *J* = 6.5 Hz, 1H, CHCH₃), 1.36 (t, *J* = 6.5 Hz, 6H, CHCH₃).

¹³C NMR (125 MHz; CDCl₃; Me₄Si), δ: 158.1 (s, CO), 143.6 (t, *J* = 30 Hz, C), 135.6 (s, C), 111.6 (tt, ¹*J*_{C-F} = 245 Hz, ²*J*_{C-F} = 28 Hz, CF₂), 109.3 (tt, ¹*J*_{C-F} = 250 Hz, ²*J*_{C-F} = 38 Hz, CF₂), 107.7 (s, CH), 69.9 (s, OCH), 21.3 (s, CH₃).

¹⁹F NMR (375 MHz; CDCl₃; CFCl₃), δ: -113.7 (pseudo q, *J* = 4.0 Hz, 2F, CF₂), -136.5 (dt, ²*J*_{F-H} = 52.0 Hz, ²*J*_{F-F} = 4.0 Hz).

MS (CI): *m/z* (%) = 255 [M+1]⁺.

Anal. calcd for C₉H₁₀F₄N₂O₂: C, 42.53; H, 3.97; N, 11.02. Found: C, 42.84; H, 4.31; N, 11.25.

Cyclobutyl[3-(1,1,2,2-tetrafluoroethyl)-1H-pyrazol-5-yl]methanone (14a)

Compound **14a** was obtained as a colorless oil (77 mg, 96%) following the general procedure.

¹H NMR (500 MHz; CDCl₃; Me₄Si), δ: 6.97 (s, 1H, CH), 6.15 (tt, ²*J*_{H-F} = 52.0 Hz, ³*J*_{H-F} = 16.0 Hz, 1H, CHF₂CF₂), 3.82 (qv, *J* = 7.0 Hz, 1H, CH), 2.46 (m, 2H), 2.33 (m, 2H), 2.14 (m, 2H).

¹³C NMR (125 MHz; CDCl₃; Me₄Si), δ: 191.4 (s, CO), 143.8 (t, *J* = 30 Hz, C), 140.2 (s, C), 111.5 (tt, ¹*J*_{C-F} = 245 Hz, ²*J*_{C-F} = 28 Hz, CF₂), 109.3 (tt, ¹*J*_{C-F} = 250 Hz, ²*J*_{C-F} = 38 Hz, CF₂), 107.0 (s, CH), 42.4 (s), 26.5 (s), 24.3 (s), 17.8 (s, CH₃).

¹⁹F NMR (375 MHz; CDCl₃; CFCl₃), δ: -113.5 (pseudo q, *J* = 4.0 Hz, 2F, CF₂), -136.6 (dt, ²*J*_{F-H} = 52.0 Hz, ²*J*_{F-F} = 4.0 Hz).

MS (CI): *m/z* (%) = 251 [M+1]⁺.

Anal. calcd for C₁₀H₁₀F₄N₂O₄: C, 48.01; H, 4.03; N, 11.20. Found: C, 48.35; H, 3.82; N, 11.49.

1-[3-(1,1,2,2-tetrafluoroethyl)-1H-pyrazol-5-yl]-2-phenylethanone (15a)

Compound **15a** was obtained as a colorless oil (87 mg, 95%) following the general procedure.

¹H NMR (500 MHz; CDCl₃; Me₄Si), δ: 7.36-7.26 (m, 5H, Ph), 7.05 (s, 1H, CH), 6.12 (tt, ²*J*_{H-F} = 52.0 Hz, ³*J*_{H-F} = 16.0 Hz, 1H, CHF₂CF₂), 4.16 (s, 2H, CH₂).

¹³C NMR (125 MHz; CDCl₃; Me₄Si), δ: 188.0 (s, CO), 143.4 (t, *J* = 28.7 Hz, CCF₂), 141.5 (s, C), 132.0 (s, Ph), 129.1 (s, Ph), 128.6 (s, Ph), 127.2 (s, Ph), 111.6 (tt, ¹*J*_{C-F} = 245 Hz, ²*J*_{C-F} = 28 Hz, CF₂), 109.3 (tt, ¹*J*_{C-F} = 250 Hz, ²*J*_{C-F} = 38 Hz, CF₂), 107.8 (s, CH), 46.1 (s, CH₂).

¹⁹F NMR (375 MHz; CDCl₃; CFCl₃), δ: -113.4 (pseudo q, *J* = 4.0 Hz, 2F, CF₂), -136.4 (dt, ²*J*_{F-H} = 52.0 Hz, ²*J*_{F-F} = 4.0 Hz).

MS (CI): *m/z* (%) = 287 [M+1]⁺.

Anal. calcd for C₁₃H₁₀F₄N₂O: C, 54.55; H, 3.52; N, 9.79. Found: C, 54.21; H, 3.78; N, 9.61.

1-[3-(1,1,2,2-tetrafluoroethyl)-1H-pyrazol-5-yl]-3-phenyl-1-propanone (16a)

Compound **16a** was obtained as a colorless oil (91 mg, 94%) following the general procedure.

¹H NMR (500 MHz; CDCl₃; Me₄Si), δ: 7.33-7.21 (m, 5H, Ph), 7.02 (s, 1H, CH), 6.12 (tt, ²*J*_{H-F} = 52.0 Hz, ³*J*_{H-F} = 16.0 Hz, 1H, CHF₂CF₂), 3.22 (t, *J* = 7.5 Hz, 2H, CH₂), 3.06 (t, *J* = 7.5 Hz, 2H, CH₂).

¹³C NMR (125 MHz; CDCl₃; Me₄Si), δ: 190.0 (s, CO), 143.4 (t, *J* = 28.5 Hz, CCF₂), 141.6 (s, C), 139.7 (s, Ph), 128.3 (s, Ph), 128.0 (s, Ph), 126.1 (s, Ph), 111.6 (tt, ¹*J*_{C-F} = 245 Hz, ²*J*_{C-F} = 28 Hz, CF₂), 109.3 (tt, ¹*J*_{C-F} = 250 Hz, ²*J*_{C-F} = 38 Hz, CF₂), 107.3 (s, CH), 40.9 (s, CH₂), 29.2 (s, CH₂).

¹⁹F NMR (375 MHz; CDCl₃; CFCl₃), δ: -113.5 (pseudo q, *J* = 4.0 Hz, 2F, CF₂), -136.4 (dt, ²*J*_{F-H} = 52.0 Hz, ²*J*_{F-F} = 4.0 Hz).

MS (CI): *m/z* (%) = 301 [M+1]⁺.

Anal. calcd for C₁₄H₁₂F₄N₂O: C, 56.00; H, 4.03; N, 9.33. Found: C, 56.34; H, 3.76; N, 9.52.

Dimethyl 3-(1,1,2,2-tetrafluoroethyl)-1H-pyrazole-4,5-dicarboxylate (17a)

Compound **17a** was obtained as a yellowish oil (83 mg, 91%) following the general procedure.

¹H NMR (500 MHz; CDCl₃; Me₄Si), δ: 6.28 (tt, ²*J*_{H-F} = 52.0 Hz, ³*J*_{H-F} = 16.0 Hz, 1H, CHF₂CF₂), 3.92 (s, 3H, CH₃), 3.90 (s, 3H, CH₃).

¹³C NMR (125 MHz; CDCl₃; Me₄Si), δ: 161.9 (s, CO), 158.0 (s, CO), 141.3 (t, *J* = 28.7 Hz, CCF₂), 134.7 (s, C), 115.6 (s, C), 111.4 (tt, ¹*J*_{C-F} = 245 Hz, ²*J*_{C-F} = 28 Hz, CF₂), 109.1 (tt, ¹*J*_{C-F} = 250 Hz, ²*J*_{C-F} = 38 Hz, CF₂), 53.8 (s, CH₃), 53.7 (s, CH₃).

¹⁹F NMR (375 MHz; CDCl₃; CFCl₃), δ: -114.9 (pseudo q, *J* = 4.0 Hz, 2F, CF₂), -137.4 (dt, ²*J*_{F-H} = 52.0 Hz, ²*J*_{F-F} = 4.0 Hz).

MS (CI): *m/z* (%) = 285 [M+1]⁺.

Anal. calcd for C₉H₈F₄N₂O₄: C, 38.04; H, 2.84; N, 9.86. Found: C, 38.37; H, 3.05; N, 9.51.

Diethyl 3-(1,1,2,2-tetrafluoroethyl)-1H-pyrazole-4,5-dicarboxylate (18a)

Compound **18a** was obtained as colorless oil (92 mg, 92%) following the general procedure.

¹H NMR (500 MHz; CDCl₃; Me₄Si), δ: 6.27 (tt, ²J_{H-F} = 52.0 Hz, ³J_{H-F} = 16.0 Hz, 1H, CHF₂CF₂), 4.41 (m, 4H, CH₂+CH₂), 1.37 (m, 6H, CH₃+CH₃).

¹³C NMR (125 MHz; CDCl₃; Me₄Si), δ: 161.4 (s, CO), 157.5 (s, CO), 141.5 (t, J = 28.7 Hz, CCF₂), 134.5 (s, C), 116.1 (s, C), *tert*-CF₂ is not seen, 109.4 (tt, ¹J_{C-F} = 250 Hz, ²J_{C-F} = 38 Hz, CF₂), 62.3 (s, OCH₂), 61.9 (s, OCH₂), 13.6 (s, CH₃), 13.5 (s, CH₃).

¹⁹F NMR (375 MHz; CDCl₃; CFCl₃), δ: -114.7 (pseudo q, J = 4.0 Hz, 2F, CF₂), -137.4 (dt, ²J_{F-H} = 52.0 Hz, ²J_{F-F} = 4.0 Hz).

MS (CI): m/z (%) = 313 [M+1]⁺.

Anal. calcd for C₁₁H₁₂F₄N₂O₄: C, 42.32; H, 3.87; N, 8.97. Found: C, 42.05; H, 4.23; N, 9.36.

5-(Diphenylphosphoryl)-3-(1,1,2,2-tetrafluoroethyl)-1H-pyrazole (19a)

Compound **19a** was obtained as a white solid (109 mg, 93%) following the general procedure. M.p. > 200 °C.

¹H NMR (500 MHz; DMSO-d₆; Me₄Si), δ: 14.66 (broad s, NH), 7.67 (broad s, 6H, *Ph+Ph*), 7.59 (broad s, 4H, *Ph+Ph*), 6.84 (pseudo t, ²J_{H-F} = 52.0 Hz, 2H, CHF₂CF₂+CH).

¹³C NMR (125 MHz; CDCl₃; Me₄Si), δ: 142.7 (broad s, C), 137.9 (d, ¹J(C,P) = 111.9 Hz, C), 132.9 (s, p-CH, Ph), 132.5 (d, ¹J(C,P) = 116.5 Hz, C), 131.2 (d, ³J(C,P) = 11.3 Hz, CH, Ph), 120.1 (d, ²J(C,P) = 12.5 Hz, CH, Ph), 111.8 (d, ²J(C,P) = 16.3 Hz, CH).

¹⁹F NMR (375 MHz; CDCl₃; CFCl₃), δ: -111.1 (pseudo q, J = 4.0 Hz, 2F, CF₂), -136.7 (dt, ²J_{F-H} = 52.0 Hz, ²J_{F-F} = 4.0 Hz).

³¹P NMR (202 MHz DMSO-d₆; H₃PO₄), δ: 14.7 (broad s, P).

MS (CI): m/z (%) = 369 [M+1]⁺.

Anal. calcd for C₁₇H₁₃F₄N₂O₂P: C, 55.45; H, 3.56; N, 7.51. Found: C, 55.11; H, 3.87; N, 7.72.

2-[3-((1,1,2,2-tetrafluoroethyl)-1H-pyrazol-5-yl)]-quinoxaline (20a)

The reaction was performed following the general procedure, except for: 5.0 eq. HCF₂CF₂CH₂NH₂*HCl + 1.0 eq. alkyne + 8.0 eq. NaNO₂. The formed product was washed out with CHCl₃ (0.5 mL) to afford the pure pyrazole **20a** a grey solid (69 mg, 73%). M.p. > 200 °C.

¹H NMR (500 MHz; DMSO-d₆; Me₄Si), δ: 14.19 (broad s, 1H, NH), 9.55 (s, 1H, CH), 8.14 (d, J = 8.0 Hz, 2H, CH), 7.91 (m, 2H, CH), 7.75 (s, 1H, CH), 6.91 (t, ²J_{H-F} = 52.0 Hz, 1H, CHF₂CF₂).

¹³C NMR (125 MHz; DMSO-d₆; Me₄Si), δ: 143.7 (s), 142.5 (s), 141.5 (s), 141.1 (s), 131.2 (s), 130.6 (s), 129.2 (s), 128.9 (s), *tert*-CF₂ is not seen, 110.0 (tt, ¹J_{C-F} = 250 Hz, ²J_{C-F} = 38 Hz, CF₂), 105.1 (s).

¹⁹F NMR (375 MHz; DMSO-d₆; CFCl₃), δ: -111.3 (broad s, 2F, CF₂), -136.5 (dt, ²J_{F-H} = 52.6 Hz, ²J_{F-F} = 7.6 Hz).

MS (CI): m/z (%) = 297 [M+1]⁺.

Anal. calcd for C₁₃H₈F₄N₄: C, 52.71; H, 2.72; N, 18.91. Found: C, 52.34; H, 2.58; N, 19.22.

Acknowledgements

All amines and alkynes were generously provided by Enamine Ltd. I am very grateful to O. Ishenko and V. Stepanenko for the kind gift of **2**. I also thank Dr. S. Shishkina for X-ray studies;

and to O. Mashkov, R. Iminov, V. Arkhipov, B. Chalyk for the help in managing this project.

Notes and references

^a Enamine Ltd., vul. Matrosova 23, 01013 Kyiv, Ukraine

^b Faculty of Chemistry, Taras Shevchenko National University of Kyiv, vul. Volodymyrska 62a, 01601 Kyiv, Ukraine

†Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/b000000x/

¹ (a) *Fluorinated Heterocyclic Compounds: Synthesis, Chemistry and Applications*, Petrov, V. A., Ed.; John Wiley & Sons, Inc., Publishers: New Jersey, 2009. (b) *Bioorganic and Medicinal Chemistry of Fluorine* (Eds.: J.-P. Bégué, D. Bonnet-Delpon), John Wiley & Sons, New Jersey, 2008; (c) *Fluorine in Medicinal Chemistry and Chemical Biology* (Ed.: I. Ojima), Blackwell Publishing, 2009; (d) *Fluorine in Pharmaceutical and Medicinal Chemistry: From Biophysical Aspects to Clinical Applications* (Eds.: V. Gouverneur, K. Müller), Imperial College Press, London, 2012.

² Recent reviews: (a) Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, C.; Sorochinsky, A. E.; Fusteero, S.; Soloshonok, V. A.; Liu, H. *Chem. Rev.* **2014**, *114*, 2432. (b) Fujiwara, T.; O'Hagan, D. *J. Fluorine Chem.* **2014**, *167*, 16. (c) O'Hagan, D. *J. Fluorine Chem.* **2010**, *131*, 1071. (d) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. *Chem. Soc. Rev.* **2008**, *37*, 320. (e) Hagmann, W. K. *J. Med. Chem.* **2008**, *51*, 4359.

³ For reviews on fluorinated pyrazoles, see: (a) Fustero, S.; Sanchez-Rosello, M.; Barrio, P.; Simon-Fuentes A. *Chem. Rev.* **2011**, *111*, 6984. (b) Giornal, F.; Pazenok, S.; Rodeföld, L.; Lui, N.; Vors, J.-P.; Leroux F. R. *J. Fluorine Chem.* **2013**, *152*, 2. (c) Fustero, S. Simon-Fuentes, A.; Sanz-Cervera, J. F. *Org. Prep. Proced. Int.*, **2009**, *41*, 253

⁴ For some recent papers on fluoroalkyl pyrazoles, see: (a) Sha, Q.; Liu, H.; Wei, Y. *Eur. J. Org. Chem.* **2014**, *34*, 7707. (b) Iminov, R. T.; Mashkov, A. V.; Vyzir, I. I.; Chalyk, B. A.; Tverdokhlebov, A. V.; Mykhailiuk, P. K.; Babichenko, L. N.; Tolmachev, A. A.; Volovenko, Y. M.; Bittseva, A.; Shishkin, O. V.; Shishkina, S. V. *Eur. J. Org. Chem.* **2014**, *in press*, DOI: 10.1002/ejoc.201403295. (c) Giornal, F.; Landelle, G.; Lui, N.; Vors, J.-P.; Pazenok, S.; Leroux, F. R. *Org. Process Res. Dev.* **2014**, *18*, 1002. (d) Roman, R.; Navarro, A.; Wodka, D.; Alvim-Gaston, M.; Husain, S.; Franklin, N.; Simón-Fuentes, A.; Fustero, S. *Org. Process Res. Dev.* **2014**, *18*, 1027. (e) Pazenok, S.; Giornal, F.; Landelle, G.; Lui, N.; Vors, J.-P.; Leroax, F. R. *Eur. J. Org. Chem.* **2013**, 4249. (f) Gerus, I. I.; Mironetz, R. X.; Kondratov, I. S.; Bezdudny, A. V.; Dmytriv, Y. V.; Shishkin, O. V.; Starova,

- V. S.; Zaporozhets, O. A.; Tolmachev, A. A.; Mykhailiuk, P. K. *J. Org. Chem.* **2012**, *77*, 47.
- ⁵ Some reviews on fluoroalkylation, see: (a) Maa, J.-A.; Cahard, D. *Chem. Rev.* **2004**, *104*, 6119. (b) Macé, Y.; Magnier, E. *Eur. J. Org. Chem.* **2012**, 2479. (c) Ni, C.; Hu, M.; Hu, J. *Chem. Rev.* **2014**, *in press*, DOI: 10.1021/cr5002386. (d) Tomashenko, O. A.; Gruushin, V. V. *Chem. Rev.* **2011**, *111*, 4475. (e) Charpentier, J.; Früh, N.; Togni, A. *Chem. Rev.* **2015**, *in press*, DOI: 10.1021/cr500223h. (f) Barata-Vallejo, S.; Lantano, B.; Postigo, A. *Chem. Eur. J.* **2014**, *20*, 16806. (g) Roy, S.; Gregg, B. T.; Gribble, G. W.; Le, V.-D.; Roy, S. *Tetrahedron* **2011**, *67*, 2161. (h) Nie, J.; Guo, H.-C.; Cahard, D.; Ma, J.-A. *Chem. Rev.* **2011**, *111*, 455.
- ⁶ Gaseous CF_3CHN_2 was first described in: Gilman, H.; Jones, R. G. *J. Am. Chem. Soc.* **1943**, *65*, 1458.
- ⁷ More than 70 papers on CF_3CHN_2 have been published so far (Reaxys DB).
- ⁸ Some recent papers on CF_3CHN_2 by different research groups: (a) Morandi, B.; Carreira, E. M. *Angew. Chem. Int. Ed.* **2010**, *49*, 938. (b) Morandi, B.; Carreira, E. M. *Angew. Chem. Int. Ed.* **2010**, *49*, 4294. (c) Morandi, B.; Carreira, E. M. *Angew. Chem. Int. Ed.* **2011**, *50*, 1101. (d) Zhang, F.-G.; Wei, Y.; Yi, Y.-P.; Nie, J.; Ma, J.-A. *Org. Lett.* **2014**, *16*, 3122. (e) Wang, S.; Nie, J.; Zheng, Y.; Ma, J.-A. *Org. Lett.* **2014**, *16*, 1606. (f) Li, F.; Nie, J.; Sun, L.; Zheng, Y.; Ma, J.-A. *Angew. Chem. Int. Ed.* **2013**, *52*, 6255. (g) Argintaru, O. A.; Ryu, D.; Aron, I.; Molander, G. A. *Angew. Chem. Int. Ed.* **2013**, *52*, 13656. (h) Molander, G. A.; Cavalcanti, L. N. *Org. Lett.* **2014**, *15*, 3166. (i) Molander, G. A.; Ryu, D. *Angew. Chem. Int. Ed.* **2014**, *53*, 14181. (j) Artamonov, O. S.; Mykhailiuk, P. K.; Voievoda, N. M.; Volochnyuk, D. M.; Komarov I. V. *Synthesis* **2010**, 443. (k) Artamonov, O. S.; Slobodyanyuk, E. Y.; Shishkin, O. V.; Komarov, I. V.; Mykhailiuk, P. K. *Synthesis* **2013**, 225. (l) Artamonov, O. S.; Slobodyanyuk, E. Y.; Volochnyuk, D. M.; Komarov I. V.; Tolmachev, A.A.; Mykhailiuk, P. K. *Eur. J. Org. Chem.* **2014**, 3592. (m) Mykhailiuk, P. K.; Afonin, S.; Palamarchuk, G. V.; Shishkin, O. V.; Ulrich, A. S.; Komarov, I. V. *Angew. Chem. Int. Ed.* **2008**, *45*, 5765. (n) Le Maux, P.; Juillard, S.; Simonneaux, G. *Synthesis* **2006**, *10*, 1701. (o) Duncton, M. A. J.; Ayala, L.; Kaub, C.; Janagani, S.; Edwards, W. T.; Orike, N.; Ramamoorthy, K.; Kincaid, J.; Kelly, M. G. *Tetrahedron Lett.* **2010**, *51*, 1009. (p) Chai, Z.; Bouillon, J.-P.; Caharrd, D. *Chem. Commun.* **2012**, *48*, 9471. (q) Duncton, M. A. J.; Singh, R. *Org. Lett.* **2013**, *15*, 4284. (r) Wu, G.; Deng, Y.; Wu, C.; Wang, X.; Zhang, Y.; Wang, J. *Eur. J. Org. Chem.* **2014**, 4477. (s) Li, T.-R.; Duan, S.-W.; Ding, W.; Liu, Y.-Y.; Chen, J.-R.; Lu, L.-Q.; Xiao, W.-J. *J. Org. Chem.* **2014**, *79*, 2296.
- ⁹ Slobodyanyuk, E. Y.; Artamonov, O. S.; Shishkin, O. V.; Mykhailiuk, P. K. *Eur. J. Org. Chem.* **2014**, 2487.
- ¹⁰ (a) P. K. Mykhailiuk *Beilstein. J. Org. Chem.* **2015**, *11*, 16. (b) P. Mykhailiuk *Chem. Eur. J.* **2014**, *17*, 4942.
- ¹¹ For a review on [3+2]-cycloadditions, see: G. Maas in *Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry toward Heterocycles and Natural Products* (Eds.: A. Padwa, W. H. Pearson), Wiley, New York, 2002, pp. 539-621.
- ¹² Y. Chiang, A. J. Kresge, V. V. Popik *J. Chem. Soc. Perkin Trans. 2*, **1999**, 1107.
- ¹³ J. H. Atherton, R. Fields, R. N. Haszeldine *J. Chem. Soc. C*, **1971**, 366.
- ¹⁴ CCDC numbers: 1036133 (**5b**), 1036138 (**6c**), 1036139 (**7c**), 1036137 (**10e**) 1036136 (**13a**), 1036134 (**19a**) and 1036135 (**23a**).
- ¹⁵ -I inductive effects of substituents: F (4.0), CF_3 (3.5), CHF_2 (2.9): Hansch, C.; Leo, A.; Taft, R. W. *Chem. Rev.* **1991**, *91*, 165.
- ¹⁶ For other methods on incorporation of tetrafluoroethyl group into organic compounds, see: (a) Chernykh, Y.; Hlat-Glembova, K.; Klepetarova, B.; Beier, P. *Eur. J. Org. Chem.* **2011**, 4528. (b) Sokolenko, T. M.; Davydova, Y. A.; Yagupolskii, Y. L. *J. Fluorine Chem.* **2012**, *136*, 20. (c) Chernykh, Y.; Jurasek, B.; Beier, P. *J. Fluorine Chem.* **2014**, *in press*, DOI: 10.1016/j.jfluchem.2014.08.004. (d) Vaclavik, J.; Chernykh, Y.; Jurasek, B.; Beier, P. *J. Fluorine Chem.* **2015**, *169*, 24.
- ¹⁷ CCDC numbers: 1036133 (**5b**), 1036138 (**6c**), 1036139 (**7c**), 1036137 (**10e**) 1036136 (**13a**), 1036134 (**19a**) and 1036135 (**23a**).